Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Renal Cell Carcinoma: Update Bulletin [October 2015]

Product Code:
596200387
Publication Date:
October 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of renal cell carcinoma (RCC). Topics covered include opinions about the Phase III CheckMate-025 study comparing Bristol-Myers Squibb’s Opdivo (nivolumab) with Novartis' Afinitor (everolimus) in patients with advanced RCC; results from the Phase III METEOR study comparing Exelixis’ Cometriq (cabozantinib) with Afinitor in RCC patients whose disease has progressed following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI); and the potential of Argos Therapeutics’ AGS-003, a personalised dendritic cell immunotherapy as a treatment for metastatic RCC.

Key Questions Answered in this Update Bulletin:

  • What are KOLs’ reactions to the efficacy demonstrated by Bristol-Myers Squibb’s Opdivo (nivolumab) in the CheckMate-025 trial?
  • If Opdivo is approved for RCC, how do KOLs anticipate using this agent?
  • How do KOLs perceive Opdivo’s side-effect profile and how do they think it will impact the future use of the drug?
  • How do KOLs view the results of the Phase III METEOR study comparing Exelixis’ Cometriq (cabozantinib) with Novartis' Afinitor (everolimus)?
  • What is the likelihood that Cometriq will gain approval?
  • If Cometriq is approved for RCC, how do KOLs anticipate using this agent?
  • How do KOLs view the potential of Argos’ AGS-003 and the likely outcome of the ADAPT study?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved